论文部分内容阅读
目的:观察经肝动脉栓塞化疗(TACE)单用或联合替吉奥与沙利度胺治疗中晚期肝细胞癌(HCC)的疗效。方法:将2010年8月-2012年8月本院收治的无法手术切除的中晚期HCC患者80例随机分为2组,每组40例。治疗组采用TACE联合替吉奥与沙利度胺口服,对照组仅行TACE治疗。比较两组的有效率、疾病控制率、生存率以及不良反应情况。结果:治疗组有效率67.5%,对照组30.0%,差异有统计学意义(P=0.001);治疗组疾病控制率92.5%,对照组37.5%,差异有统计学意义(P=0.000)。治疗组1年生存率80.0%,对照组50.0%,差异有统计学意义(P=0.005);治疗组2年生存率42.5%,对照组10.0%,差异有统计学意义(P=0.001)。两组不良反应轻微,主要为恶心呕吐、便秘和骨髓抑制,为I、II级,对症治疗可缓解,两组比较差异无统计学意义(P>0.05)。结论:替吉奥与沙利度胺联合TACE术对中晚期HCC有一定的治疗价值,值得进一步观察。
Objective: To evaluate the efficacy of TACE alone or combined with tegafur and thalidomide in the treatment of advanced hepatocellular carcinoma (HCC). METHODS: Eighty patients with unresectable advanced HCC treated from August 2010 to August 2012 were randomly divided into 2 groups, 40 in each group. The treatment group was treated with TACE combined with tegio and thalidomide, and the control group was treated with TACE only. The efficacy, disease control rate, survival rate, and adverse reactions were compared between the two groups. Results: The effective rate was 67.5% in the treatment group and 30.0% in the control group (P=0.001). The disease control rate was 92.5% in the treatment group and 37.5% in the control group. The difference was statistically significant (P=0.000). The 1-year survival rate was 80.0% in the treatment group and 50.0% in the control group (P=0.005). The 2-year survival rate was 42.5% in the treatment group and 10.0% in the control group. The difference was statistically significant (P=0.001). The adverse reactions in the two groups were mild, mainly nausea, vomiting, constipation and bone marrow suppression, which were Grade I and II. Symptomatic treatment could be alleviated. There was no significant difference between the two groups (P>0.05). Conclusion: The combination of tegafur and thalidomide with TACE has certain therapeutic value for advanced HCC, and it is worth further observation.